Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. 1990

P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
Department of Microbiology and Immunology, Baylor College of Medicine, Houston, Texas 77030.

The toxicity and antiviral efficacy of carbocyclic 3-deazaadenosine (Cc3Ado) against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) virus infections were tested in tissue culture and in cotton rats. The mean median efficacious dose (ED50) of Cc3Ado in HEp2 cells against RSV and PIV3 was 9 and 14 micrograms/ml, respectively. These values were 85- and 55-fold less than the median inhibitory (toxic) dose (ID50) of Cc3Ado in this cell line (750 micrograms/ml), and similar to values obtained for ribavirin. Cc3Ado exhibited no significant antiviral activity against influenza A, influenza B, adeno type 5 or adeno type 7 viruses (all ED50 were greater than 1000 micrograms/ml). In cotton rats, animals given greater than or equal to 1 mg/kg/day Cc3Ado intraperitoneally on days 1, 2 and 3 after experimental challenge with virus, consistently had significant reductions in pulmonary RSV and PIV3 titers compared to pulmonary virus titers in comparably treated control animals. The minimum efficacious dose of ribavirin given under the same conditions was 30 mg/kg/day. Cc3Ado was also efficacious in cotton rats when given orally by gavage, or when different administration schedules were used. The median efficacious dose of Cc3Ado when given orally was 10 mg/kg/day. No significant toxic effects were noted in cotton rats, even in animals given 20 mg/kg daily for eight consecutive days.

UI MeSH Term Description Entries
D008297 Male Males
D010224 Parainfluenza Virus 3, Human A species of RESPIROVIRUS frequently isolated from small children with pharyngitis, bronchitis, and pneumonia. Hemadsorption Virus 1,Human parainfluenza virus 3,Para-Influenza Virus Type 3,Parainfluenza Virus Type 3,Para Influenza Virus Type 3
D010253 Respirovirus Infections Infections with viruses of the genus RESPIROVIRUS, family PARAMYXOVIRIDAE. Host cell infection occurs by adsorption, via HEMAGGLUTININ, to the cell surface. Infections, Respirovirus
D012136 Respiratory Syncytial Viruses A group of viruses in the PNEUMOVIRUS genus causing respiratory infections in various mammals. Humans and cattle are most affected but infections in goats and sheep have also been reported. Chimpanzee Coryza Agent,Orthopneumovirus,RSV Respiratory Syncytial Virus,Chimpanzee Coryza Agents,Coryza Agent, Chimpanzee,Orthopneumoviruses,Respiratory Syncytial Virus,Syncytial Virus, Respiratory,Virus, Respiratory Syncytial
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
April 1998, Antiviral research,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
March 1983, Antiviral research,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
January 1993, Drug metabolism and disposition: the biological fate of chemicals,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
December 2022, Emerging microbes & infections,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
September 1993, The Journal of general virology,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
August 1994, Bio/technology (Nature Publishing Company),
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
December 1981, Antimicrobial agents and chemotherapy,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
August 1964, The New Zealand medical journal,
P R Wyde, and M W Ambrose, and H L Meyer, and C L Zolinski, and B E Gilbert
January 2013, Methods in molecular biology (Clifton, N.J.),
Copied contents to your clipboard!